Global Proprotein Convertase Subtilisin Kexin 9 (PCSK-9) Inhibitors Pipeline Insights Report 2016 – Research and Markets
July 8, 2016 | By Business Wire News
DUBLIN
Research and Markets has announced the addition of the “Proprotein Convertase Subtilisin Kexin 9 (PCSK-9) Inhibitors – Pipeline Insights, 2016” report to their offering.
Proprotein Convertase Subtilisin Kexin 9 (PCSK-9) Inhibitors-Pipeline Insights, 2016 provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Proprotein Convertase Subtilisin Kexin 9 (PCSK-9) Inhibitors.
Report Highlights:
– The new report, provides a Proprotein Convertase Subtilisin Kexin 9 (PCSK-9) Inhibitors Landscape across the globe
– The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information
– Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages
– Coverage of the Proprotein Convertase Subtilisin Kexin 9 (PCSK-9) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
– The report reviews key players involved in the therapeutics development for PCSK-9 Inhibitors and also provide company profiling
– Pipeline products coverage based on various stages of development from NDA filings to discovery.
– Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.
Key Topics Covered:
- Overview
- Epidemiology
- Market Scenario
- Pipeline Therapeutics
- An Overview of Pipeline Products for PCSK-9 Inhibitors
- Therapeutics under Development by Companies
- Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Mid Stage Products (Phase II)
- Comparative Analysis
- Product Description
- Product Development Activities
- Early Stage Products (Phase I and IND)
- Comparative Analysis
- Discovery and Pre-clinical stage Products
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Discontinued Products
- Dormant Products
- Companies involved in Therapeutics Development
– Pfizer
– Serometrix
– Bristol-Myers Squibb/Ionis
– Shifa Biomedical
For more information visit http://www.researchandmarkets.com/research/2xn2wd/proprotein
View source version on businesswire.com: http://www.businesswire.com/news/home/20160708005721/en/
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Enzymes, Food Additive Chemicals
